Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) – Analysts at Cantor Fitzgerald boosted their FY2022 earnings per share (EPS) estimates for Marinus Pharmaceuticals in a note issued to investors on Monday, November 14th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will post earnings per share of ($0.40) for the year, up from their prior forecast of ($0.71). The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($0.49) per share. Cantor Fitzgerald also issued estimates for Marinus Pharmaceuticals’ FY2023 earnings at ($1.62) EPS.
MRNS has been the subject of several other research reports. StockNews.com upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday. HC Wainwright dropped their price target on Marinus Pharmaceuticals from $38.00 to $27.00 in a research report on Wednesday, November 9th. Finally, Robert W. Baird dropped their price target on Marinus Pharmaceuticals from $32.00 to $24.00 and set an “outperform” rating for the company in a research report on Wednesday, November 9th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.43.
Marinus Pharmaceuticals Trading Down 2.2 %
Institutional Trading of Marinus Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new stake in Marinus Pharmaceuticals in the first quarter worth about $40,000. Amalgamated Bank bought a new stake in Marinus Pharmaceuticals in the first quarter worth about $56,000. PDT Partners LLC bought a new stake in shares of Marinus Pharmaceuticals during the second quarter valued at approximately $63,000. Laurion Capital Management LP bought a new stake in shares of Marinus Pharmaceuticals during the second quarter valued at approximately $74,000. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Marinus Pharmaceuticals by 39.5% during the second quarter. Price T Rowe Associates Inc. MD now owns 15,600 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 4,417 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
- Get a free copy of the StockNews.com research report on Marinus Pharmaceuticals (MRNS)
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.